Johnston SC, et al. - Given that lower major ischemic events but higher major hemorrhage were reported relative to the combination of clopidogrel and aspirin for 90 days vs aspirin alone in patients treated for acute minor ischemic stroke or high-risk transient ischemic attack in the POINT trial, researchers evaluated the time course for gain and risk from the combination of clopidogrel and aspirin in this secondary analysis of POINT involving 4,881 patients. A composite of ischemic stroke, myocardial infarction, or ischemic vascular death was assessed as a primary efficacy outcome. Major hemorrhage was considered the primary safety outcome. Within the first 21 days, clopidogrel-aspirin-induced benefit was predominantly evident and outweighed the low, but ongoing risk of major hemorrhage. The benefit from clopidogrel-aspirin may be maximized and risk may be attenuated after high-risk TIA or minor ischemic stroke if clopidogrel-aspirin use is limited to 21 days.